This randomized, double‑blind, placebo‑controlled study found that a 30‑s bolus followed by a 6‑hour intravenous DMT infusion (maximal exposures ≈35 ng/mL) was well tolerated in healthy volunteers with no serious adverse events and only mild, rapidly occurring psychedelic effects. Moderate interindividual pharmacokinetic variability was observed and the highest dose produced transient reductions in sustained attention, postural stability and occipital alpha power, providing a safety and PK/PD basis for future proof‑of‑mechanism studies in patient populations.
- Published
- Journal
- Clinical and Translational Science
- Authors
- Zuiker, R. G. J. A., Otto, M. E., Bryan, C. S., Stewart, N., Stillwell, C., de Kam, M. L., van Leuken, M. B., van Gerven, J. M. A., Jacobs, G. E., van der Heijden, K. V.